Cadrenal to seek FDA Rare Pediatric Disease Designation for Tecarfarin
Cadrenal Therapeutics, Inc. announced its plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for tecarfarin. This designation targets pediatric patients with Kawasaki disease who develop coronary artery aneurysms and require chronic oral anticoagulation. If granted and subsequently approved, the company would be eligible for a Priority Review Voucher, which has recently been valued between $180 million and $205 million. Additionally, Cadrenal outlined a dual-track portfolio strategy, focusing on CAD-1005 for global pharmaceutical opportunities and tecarfarin for regional and rare disease markets.
Key Highlights
- Cadrenal plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin.
- Tecarfarin is intended for pediatric patients with Kawasaki disease who develop coronary artery aneurysms and require chronic oral anticoagulation.
- If RPDD is granted and tecarfarin is approved, Cadrenal could receive a Priority Review Voucher (PRV).
- Recent open-market valuations for PRVs have ranged from $180 million to $205 million.
- The company disclosed a dual-track portfolio strategy: Global Pharma Track (CAD-1005) and Regional & Rare Disease Track (tecarfarin).
- CAD-1005 is Phase 3-ready for Heparin-Induced Thrombocytopenia (HIT) and advancing into a Phase 2a trial for Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI).
- Tecarfarin is a novel Vitamin K antagonist designed to offer more reliable and consistent anticoagulation than warfarin.
- Kawasaki disease is the leading cause of acquired heart disease in children in developed nations.
Price Impact
More from CVKD
Cadrenal to Seek FDA Rare Pediatric Designation for Tecarfarin; Potential $200M PRV
Cadrenal Therapeutics CFO Matthew Szot Departs; Interim CFO Appointed
Cadrenal Therapeutics to Present at Lytham Partners Spring 2026 Investor Conference